{"id":"https://openalex.org/W4400780324","doi":"https://doi.org/10.1007/s00204-024-03794-3","title":"Identification of reversible OATP1B1 and time-dependent CYP3A4 inhibition as the major risk factors for drug-induced cholestasis (DIC)","display_name":"Identification of reversible OATP1B1 and time-dependent CYP3A4 inhibition as the major risk factors for drug-induced cholestasis (DIC)","publication_year":2024,"publication_date":"2024-07-18","ids":{"openalex":"https://openalex.org/W4400780324","doi":"https://doi.org/10.1007/s00204-024-03794-3","pmid":"https://pubmed.ncbi.nlm.nih.gov/39023798"},"language":"en","primary_location":{"id":"doi:10.1007/s00204-024-03794-3","doi":"https://doi.org/10.1007/s00204-024-03794-3","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s00204-024-03794-3","pdf_url":null,"source":{"id":"https://openalex.org/S87018847","display_name":"Archives of Toxicology","issn_l":"0340-5761","issn":["0340-5761","1432-0738"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Archives of Toxicology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","datacite","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.zora.uzh.ch/id/eprint/261600/1/ZORA_261600.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5096882835","display_name":"Vlasia Kastrinou\u2010Lampou","orcid":"https://orcid.org/0000-0001-8687-9885","observed_orcids":["https://orcid.org/0000-0001-8687-9885"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I202697423","display_name":"University of Zurich","ror":"https://ror.org/02crff812","country_code":"CH","type":"education","lineage":["https://openalex.org/I202697423"]},{"id":"https://openalex.org/I4210100468","display_name":"University Hospital Zurich","ror":"https://ror.org/01462r250","country_code":"CH","type":"healthcare","lineage":["https://openalex.org/I4210100468"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Vlasia Kastrinou-Lampou","raw_affiliation_strings":["Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Zurich, Switzerland","Pharmacokinetic Sciences, BioMedical Research, Novartis, Basel, Switzerland","Preclinical Safety, BioMedical Research, Novartis, Basel, Switzerland"],"raw_orcid":"https://orcid.org/0000-0001-8687-9885","affiliations":[{"raw_affiliation_string":"Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Zurich, Switzerland","institution_ids":["https://openalex.org/I202697423","https://openalex.org/I4210100468"]},{"raw_affiliation_string":"Pharmacokinetic Sciences, BioMedical Research, Novartis, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]},{"raw_affiliation_string":"Preclinical Safety, BioMedical Research, Novartis, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038390721","display_name":"Raquel Rodr\u00edguez-P\u00e9rez","orcid":"https://orcid.org/0000-0002-2992-3402","observed_orcids":["https://orcid.org/0000-0002-2992-3402"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Raquel Rodr\u00edguez-P\u00e9rez","raw_affiliation_strings":["Pharmacokinetic Sciences, BioMedical Research, Novartis, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacokinetic Sciences, BioMedical Research, Novartis, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029829127","display_name":"Birk Poller","orcid":"https://orcid.org/0000-0002-1181-7572","observed_orcids":["https://orcid.org/0000-0002-1181-7572"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Birk Poller","raw_affiliation_strings":["Pharmacokinetic Sciences, BioMedical Research, Novartis, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacokinetic Sciences, BioMedical Research, Novartis, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025293905","display_name":"Felix Huth","orcid":"https://orcid.org/0000-0002-7121-4394","observed_orcids":["https://orcid.org/0000-0002-7121-4394"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Felix Huth","raw_affiliation_strings":["Pharmacokinetic Sciences, BioMedical Research, Novartis, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacokinetic Sciences, BioMedical Research, Novartis, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011881964","display_name":"Zsuzsanna G\u00e1borik","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zsuzsanna G\u00e1borik","raw_affiliation_strings":["SOLVO Biotechnology, Charles River Laboratories Hungary, 1117, Budapest, Hungary"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"SOLVO Biotechnology, Charles River Laboratories Hungary, 1117, Budapest, Hungary","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104703022","display_name":"Be\u00e1ta M\u00e1rtonn\u00e9-T\u00f3th","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Be\u00e1ta M\u00e1rtonn\u00e9-T\u00f3th","raw_affiliation_strings":["SOLVO Biotechnology, Charles River Laboratories Hungary, 1117, Budapest, Hungary"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"SOLVO Biotechnology, Charles River Laboratories Hungary, 1117, Budapest, Hungary","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016711930","display_name":"Csilla Temesszentandr\u00e1si\u2010Ambrus","orcid":"https://orcid.org/0000-0002-1348-8725","observed_orcids":["https://orcid.org/0000-0002-1348-8725"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Csilla Temesszentandr\u00e1si-Ambrus","raw_affiliation_strings":["SOLVO Biotechnology, Charles River Laboratories Hungary, 1117, Budapest, Hungary"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"SOLVO Biotechnology, Charles River Laboratories Hungary, 1117, Budapest, Hungary","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108061804","display_name":"Heiko S. Schadt","orcid":"https://orcid.org/0000-0002-1164-1140","observed_orcids":["https://orcid.org/0000-0002-1164-1140"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Heiko S. Schadt","raw_affiliation_strings":["Preclinical Safety, BioMedical Research, Novartis, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Preclinical Safety, BioMedical Research, Novartis, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089543992","display_name":"Gerd Achim Kullak-Ublick","orcid":"https://orcid.org/0000-0002-0757-4408","observed_orcids":["https://orcid.org/0000-0002-0757-4408"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I202697423","display_name":"University of Zurich","ror":"https://ror.org/02crff812","country_code":"CH","type":"education","lineage":["https://openalex.org/I202697423"]},{"id":"https://openalex.org/I4210100468","display_name":"University Hospital Zurich","ror":"https://ror.org/01462r250","country_code":"CH","type":"healthcare","lineage":["https://openalex.org/I4210100468"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Gerd A. Kullak-Ublick","raw_affiliation_strings":["Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Zurich, Switzerland","Mechanistic Safety, CMO & Patient Safety, Global Drug Development, Novartis, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Zurich, Switzerland","institution_ids":["https://openalex.org/I202697423","https://openalex.org/I4210100468"]},{"raw_affiliation_string":"Mechanistic Safety, CMO & Patient Safety, Global Drug Development, Novartis, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041823454","display_name":"Michael Arand","orcid":"https://orcid.org/0000-0003-2413-3177","observed_orcids":["https://orcid.org/0000-0003-2413-3177"]},"institutions":[{"id":"https://openalex.org/I202697423","display_name":"University of Zurich","ror":"https://ror.org/02crff812","country_code":"CH","type":"education","lineage":["https://openalex.org/I202697423"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Michael Arand","raw_affiliation_strings":["Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland","institution_ids":["https://openalex.org/I202697423"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5006891741","display_name":"Gian Camenisch","orcid":"https://orcid.org/0000-0001-9637-6456","observed_orcids":["https://orcid.org/0000-0001-9637-6456"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":true,"raw_author_name":"Gian Camenisch","raw_affiliation_strings":["Pharmacokinetic Sciences, BioMedical Research, Novartis, Basel, Switzerland. gian.camenisch@novartis.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacokinetic Sciences, BioMedical Research, Novartis, Basel, Switzerland. gian.camenisch@novartis.com","institution_ids":["https://openalex.org/I1283582996"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5006891741"],"corresponding_institution_ids":["https://openalex.org/I1283582996"],"apc_list":{"value":5490,"currency":"USD","value_usd":5490},"apc_paid":null,"fwci":1.4466,"has_fulltext":false,"cited_by_count":6,"citation_normalized_percentile":{"value":0.78286649,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"98","issue":"10","first_page":"3409","last_page":"3424"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11465","display_name":"Drug-Induced Hepatotoxicity and Protection","score":0.7294999957084656,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11465","display_name":"Drug-Induced Hepatotoxicity and Protection","score":0.7294999957084656,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.25929999351501465,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.003100000089034438,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/drug-induced-cholestasis","display_name":"drug-induced cholestasis","score":1.0},{"id":"https://openalex.org/keywords/drug-induced-liver-injury","display_name":"drug-induced liver injury","score":0.9959999918937683},{"id":"https://openalex.org/keywords/oatp1b1","display_name":"OATP1B1","score":0.9269999861717224},{"id":"https://openalex.org/keywords/cyp3a4","display_name":"CYP3A4","score":0.921999990940094},{"id":"https://openalex.org/keywords/time-dependent-inhibition","display_name":"time-dependent inhibition","score":0.9459999799728394},{"id":"https://openalex.org/keywords/reversible-inhibition","display_name":"reversible inhibition","score":0.7950000166893005},{"id":"https://openalex.org/keywords/bile-acid-homeostasis","display_name":"bile acid homeostasis","score":0.8389999866485596},{"id":"https://openalex.org/keywords/bile-acid-transporters","display_name":"bile acid transporters","score":0.7680000066757202},{"id":"https://openalex.org/keywords/marketed-drugs","display_name":"marketed drugs","score":0.6620000004768372},{"id":"https://openalex.org/keywords/species-differences","display_name":"species differences","score":0.7839999794960022}],"concepts":[{"id":"https://openalex.org/C2778593092","wikidata":"https://www.wikidata.org/wiki/Q1075923","display_name":"Cholestasis","level":2,"score":0.6954770088195801},{"id":"https://openalex.org/C2779399885","wikidata":"https://www.wikidata.org/wiki/Q413288","display_name":"Bile acid","level":2,"score":0.644925594329834},{"id":"https://openalex.org/C2775905019","wikidata":"https://www.wikidata.org/wiki/Q192572","display_name":"In silico","level":3,"score":0.5946234464645386},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.5934585332870483},{"id":"https://openalex.org/C123584848","wikidata":"https://www.wikidata.org/wiki/Q18034026","display_name":"Organic anion transporter 1","level":4,"score":0.5854455828666687},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.520465612411499},{"id":"https://openalex.org/C526171541","wikidata":"https://www.wikidata.org/wiki/Q407693","display_name":"Cytochrome P450","level":3,"score":0.5047086477279663},{"id":"https://openalex.org/C89311334","wikidata":"https://www.wikidata.org/wiki/Q1124842","display_name":"Drug metabolism","level":3,"score":0.46387943625450134},{"id":"https://openalex.org/C109650736","wikidata":"https://www.wikidata.org/wiki/Q424440","display_name":"CYP3A4","level":4,"score":0.45446696877479553},{"id":"https://openalex.org/C149011108","wikidata":"https://www.wikidata.org/wiki/Q652985","display_name":"Transporter","level":3,"score":0.43161600828170776},{"id":"https://openalex.org/C2776637226","wikidata":"https://www.wikidata.org/wiki/Q6658207","display_name":"Liver injury","level":2,"score":0.42192837595939636},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.38444915413856506},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.35228949785232544},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.3510952889919281},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.32590240240097046},{"id":"https://openalex.org/C62231903","wikidata":"https://www.wikidata.org/wiki/Q1057","display_name":"Metabolism","level":2,"score":0.30278414487838745},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2435547411441803},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D001647","descriptor_name":"Bile Acids and Salts","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D002779","descriptor_name":"Cholestasis","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D002779","descriptor_name":"Cholestasis","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012307","descriptor_name":"Risk Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013997","descriptor_name":"Time Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D027381","descriptor_name":"Liver-Specific Organic Anion Transporter 1","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D051544","descriptor_name":"Cytochrome P-450 CYP3A","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D056486","descriptor_name":"Chemical and Drug Induced Liver Injury","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":true},{"descriptor_ui":"D065692","descriptor_name":"Cytochrome P-450 CYP3A Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":5,"locations":[{"id":"doi:10.1007/s00204-024-03794-3","doi":"https://doi.org/10.1007/s00204-024-03794-3","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s00204-024-03794-3","pdf_url":null,"source":{"id":"https://openalex.org/S87018847","display_name":"Archives of Toxicology","issn_l":"0340-5761","issn":["0340-5761","1432-0738"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Archives of Toxicology","raw_type":"journal-article"},{"id":"pmid:39023798","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/39023798","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Archives of toxicology","raw_type":"Journal Article"},{"id":"pmh:oai:www.zora.uzh.ch:261600","doi":null,"is_oa":true,"landing_page_url":"https://www.zora.uzh.ch/id/eprint/261600/1/ZORA_261600.pdf","pdf_url":"https://www.zora.uzh.ch/id/eprint/261600/1/ZORA_261600.pdf","source":{"id":"https://openalex.org/S4306401281","display_name":"Zurich Open Repository and Archive (University of Zurich)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I202697423","host_organization_name":"University of Zurich","host_organization_lineage":["https://openalex.org/I202697423"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Kastrinou-Lampou, Vlasia; Rodr\u00edguez-P\u00e9rez, Raquel; Poller, Birk; Huth, Felix; G\u00e1borik, Zsuzsanna; M\u00e1rtonn\u00e9-T\u00f3th, Be\u00e1ta; Temesszentandr\u00e1si-Ambrus, Csilla; Schadt, Heiko S; Kullak-Ublick, Gerd A; Arand, Michael; Camenisch, Gian (2024). Identification of reversible OATP1B1 and time-dependent CYP3A4 inhibition as the major risk factors for drug-induced cholestasis (DIC). Archives of Toxicology, 98(10):3409-3424.","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:www.zora.uzh.ch:20.500.14742/220830","doi":null,"is_oa":false,"landing_page_url":"https://www.zora.uzh.ch/handle/20.500.14742/220830","pdf_url":null,"source":{"id":"https://openalex.org/S4306401281","display_name":"Zurich Open Repository and Archive (University of Zurich)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I202697423","host_organization_name":"University of Zurich","host_organization_lineage":["https://openalex.org/I202697423"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Kastrinou-Lampou, V., Rodr\u00edguez-P\u00e9rez, R., Poller, B., Huth, F., G\u00e1borik, Z., M\u00e1rtonn\u00e9-T\u00f3th, B., Temesszentandr\u00e1si-Ambrus, C., Schadt, H. S., Kullak-Ublick, G. A., Arand, M., & Camenisch, G. (2024). Identification of reversible OATP1B1 and time-dependent CYP3A4 inhibition as the major risk factors for drug-induced cholestasis (DIC). Archives of Toxicology, 98, 3409\u20133424. https://doi.org/10.1007/s00204-024-03794-3","raw_type":"Journal Article"},{"id":"doi:10.5167/uzh-261600","doi":"https://doi.org/10.5167/uzh-261600","is_oa":true,"landing_page_url":"https://doi.org/10.5167/uzh-261600","pdf_url":null,"source":{"id":"https://openalex.org/S4306401281","display_name":"Zurich Open Repository and Archive (University of Zurich)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I202697423","host_organization_name":"University of Zurich","host_organization_lineage":["https://openalex.org/I202697423"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"JournalArticle"}],"best_oa_location":{"id":"pmh:oai:www.zora.uzh.ch:261600","doi":null,"is_oa":true,"landing_page_url":"https://www.zora.uzh.ch/id/eprint/261600/1/ZORA_261600.pdf","pdf_url":"https://www.zora.uzh.ch/id/eprint/261600/1/ZORA_261600.pdf","source":{"id":"https://openalex.org/S4306401281","display_name":"Zurich Open Repository and Archive (University of Zurich)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I202697423","host_organization_name":"University of Zurich","host_organization_lineage":["https://openalex.org/I202697423"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Kastrinou-Lampou, Vlasia; Rodr\u00edguez-P\u00e9rez, Raquel; Poller, Birk; Huth, Felix; G\u00e1borik, Zsuzsanna; M\u00e1rtonn\u00e9-T\u00f3th, Be\u00e1ta; Temesszentandr\u00e1si-Ambrus, Csilla; Schadt, Heiko S; Kullak-Ublick, Gerd A; Arand, Michael; Camenisch, Gian (2024). Identification of reversible OATP1B1 and time-dependent CYP3A4 inhibition as the major risk factors for drug-induced cholestasis (DIC). Archives of Toxicology, 98(10):3409-3424.","raw_type":"info:eu-repo/semantics/article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":39,"referenced_works":["https://openalex.org/W1205807418","https://openalex.org/W1256838432","https://openalex.org/W1550259003","https://openalex.org/W1999587831","https://openalex.org/W2002121467","https://openalex.org/W2029436392","https://openalex.org/W2036155956","https://openalex.org/W2055572009","https://openalex.org/W2061569374","https://openalex.org/W2077796674","https://openalex.org/W2078810890","https://openalex.org/W2081126191","https://openalex.org/W2087577664","https://openalex.org/W2092910855","https://openalex.org/W2104209550","https://openalex.org/W2116903203","https://openalex.org/W2134837921","https://openalex.org/W2135313054","https://openalex.org/W2140065347","https://openalex.org/W2144815258","https://openalex.org/W2144948193","https://openalex.org/W2153538952","https://openalex.org/W2162578475","https://openalex.org/W2168538436","https://openalex.org/W2172134989","https://openalex.org/W2289901683","https://openalex.org/W2315716184","https://openalex.org/W2499008247","https://openalex.org/W2593557173","https://openalex.org/W2776265394","https://openalex.org/W2793693764","https://openalex.org/W2904897856","https://openalex.org/W2957033052","https://openalex.org/W2987481746","https://openalex.org/W3128792537","https://openalex.org/W3164417722","https://openalex.org/W3182824931","https://openalex.org/W3213272676","https://openalex.org/W4313418870"],"related_works":["https://openalex.org/W4404348955","https://openalex.org/W6892236010","https://openalex.org/W2956360929","https://openalex.org/W2979935841","https://openalex.org/W2835694964","https://openalex.org/W4327966545","https://openalex.org/W7037856462","https://openalex.org/W3088938643","https://openalex.org/W4313545481","https://openalex.org/W2187816658"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2024-07-19T00:00:00"}